Status:
WITHDRAWN
HepaRAS Trial: Changes in Hepatectomy Risk Assessment When Using Mebrofenin HIDA
Lead Sponsor:
Boris Gala Lopez
Collaborating Sponsors:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Liver Failure as A Complication of Care
30-day Mortality
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Surgical procedures to remove a significant portion of the liver are used to treat various diseases including cancer. They have demonstrated to be the most effective treatment for selected patients. T...
Detailed Description
Surgical procedures to remove a significant portion of the liver are used to treat various diseases, including cancer. They have been demonstrated to be the most effective treatment for selected patie...
Eligibility Criteria
Inclusion
- All adult patients who are being considered for major hepatectomy at the QEII and McGill for malignant or benign disease.
- Both open and laparoscopic approaches will be accepted in the study.
- Patients with underlying liver cirrhosis or receiving additional ablation therapies will not be excluded.
Exclusion
- Patients younger than 18 years-old.
- Pregnant patients.
- Hepatectomy is associated with another major non-liver procedure.
- Patients not qualifying for a major hepatectomy following preoperative assessment.
Key Trial Info
Start Date :
January 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05280990
Start Date
January 15 2023
End Date
July 30 2025
Last Update
February 7 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.